Selodenoson is a potent and highly selective adenosine A1 agonist, under development by Aderis Pharmaceuticals and Fujisawa
Under the terms of the agreement, Cardiome and Fujisawa
Healthcare will co-develop RSD1235 as an intravenous formulation for the treatment of atrial fibrillation and atrial flutter for North American markets.
Director, Product Planning, Global Corporate Strategic Planning of Fujisawa
stated, "Severe Insulin Resistance can be a life threatening and severely debilitating condition.
The Agreement gives Fujisawa
the exclusive right to enter into a distribution agreement with Hemispherx for the described territory at or before an undisclosed date.
has long been committed to cardiology," stated Hideo Fukumoto, chairman and chief executive officer, Fujisawa
0 million milestone payment from Fujisawa
to CV Therapeutics.
will, subject to consent of the NCI, transfer and assign to Gloucester its obligations under the ongoing CRADA.
For the full year, Fujisawa
expects a pretax profit of 44.
AGI-1096 is a novel, oral agent that is being developed for the prevention of organ transplant rejection in collaboration with Fujisawa
a privately held drug design and development company, announced today that it has concluded its first institutional round of financing, raising $8 million, including a direct investment by Fujisawa
Investments for Entrepreneurship, L.
He will also discuss Aderis Pharmaceuticals' development partnerships with Fujisawa
Healthcare, Schwarz Pharma and King Pharmaceuticals, and the Company's financial position.
Aderis Pharmaceuticals announced the receipt of a $2 million milestone payment from its partner, Fujisawa
Healthcare, Inc (Fujisawa